Specifications tableSubjectPublic Health and Health PolicySpecific subject areaHealth Economics, Medical TechnologyType of dataStata data file, Stata code, and Spreadsheet fileHow data were acquiredExtraction from public databasesData formatRaw, AnalysedParameters for data collectionStart date and end date based on availability of monthly data for all variables.Description of data collectionData was extracted via queries executed directly in the databases. Some of the variables were constructed using variables from several database tables.Data source location(1)Drug Canada Product Database, Health Canada, Canada(2)National Library of Medicine, National Institutes of Health, United States ([www.clinicaltrials.gov](http://www.clinicaltrials.gov){#interref0001})Data accessibilityWith the article

Value of the data {#sec0001a}
=================

•The new set of variables for medical technology introduced here are conceptually attractive and add depth to existent measures. While clinical trials successfully represent general developments in medical knowledge, the drug variables capture new ready to use technology.•This data is particularly relevant to academics in fields of health economics, population health and public policy, as well as to professionals in healthcare policy, planning, investment, and management.•Variables can be incorporated into empirical research involving medical technology. This could include, for example, work related to innovation, drivers of healthcare expenditure, technology assessment and adoption rates, among others.•Provided descriptive statistics facilitate data interpretation for explorative studies and illustrative insights.•Accurate variables for medical technology are crucial when making informed decisions on cost-effective technology that could increase overall quality and specialized support in healthcare services.

1. Data description {#sec0001}
===================

This paper compiles three proxies for medical technology. As defined by the World Health Organization, medical technology comprises every "application of organized knowledge and skills in the form of medicines, medical devices, vaccines, procedures and systems developed to solve a health problem and improve quality of life" [@bib0001]. The new proxies (variables) for medical technology presented here were initially compiled to complement and also overcome some of the limitations of the existent proxies such as expenses on research and development. The validity of the dataset now made available goes beyond a health context and can be extended to research involving medical technology from a variety of fields and approaches.

All variables presented here use data from publicly accessible sources. The code made available with this article can be used to extend the series when updated information becomes available. The time series of over 250 data points (monthly information from 1997 to 2017) allows the researcher to further investigate their relationships and dynamics using a variety of time series techniques and prediction models.

The first variable is a count of completed clinical trial recruitments (CTR) per month. This was obtained from the National Library of Medicine at the National Institutes of Health, which contains a database on clinical trials conducted in 204 countries, including the United States.[1](#cit_1){ref-type="fn"} A clinical trial is defined as, "a research study in which human volunteers are assigned to interventions (for example, a medical product, behavior, or procedure) based on a protocol (or plan) and are then evaluated for effects on biomedical or health outcomes" [@bib0002]. This global medical technology proxy is attractive because it includes advances in medical knowledge such as procedures and tests that are at an advanced stage of research in addition to drugs and devices.

The second and third variables are newly-marketed drugs (NMD), and newly-marketed drugs with new active ingredients (NAI). Both were obtained from the Health Canada Drug Product Database, which provides information on drugs approved for use in Canada. NAI is a subset of NMD, which identifies the newly-marketed drugs which are highly innovative. A drug is considered highly innovative if it "contains a medical ingredient not previously approved in a drug by the Minister and that is not a variation of a previously approved medicinal ingredient" [@bib0003]. NMD excludes NAI, which allows the simultaneous inclusion of both variables in empirical estimations. Both medical technology proxies overcome some of the disadvantages of using research and development expenditure or patent data since it includes medical technology that is ready to use in the market. Despite NMD and NAI being constructed based on newly-marketed drugs in Canada, this proxy is relevant beyond Canada because pharmaceutical companies are working to have their drugs approved for use globally simultaneously, to fully benefit from patent laws.

A set of files is made available with this article to allow replication. This include Stata files of the raw data, Stata code as well as a Microsoft Excel spreadsheet with the final database. All files were obtained and/or processed in the following order:1.Stata data files (raw data): set of four files containing selected variables of interest downloaded from the original sources (after specific search queries were executed as explained in the section below).2.Stata code: code to be executed on the previous raw data to clean the files and combine existent variables to obtain the desired medical technology proxies3.Excel Spreadsheet: final medical technology proxies as obtained after running the Stata code on the raw data. The spreadsheet also contains modifications to the technology proxies after incorporating depreciation rates (explained below), as well as all tables and graphs obtained to describe the data.

2. Experimental design, materials, and methods {#sec0002}
==============================================

Data for CTR, NMD and NAI was collected directly from the websites of the National Library of Medicine and the Health Canada Drug Product Database Drug and the search queries included the following set of parameters:•For the case of clinical trials, information was obtained from [www.clinicaltrials.gov](http://www.clinicaltrials.gov){#interref0002} and gathered through the advanced search feature by selecting those studies where *Study Type* was "All studies" and *Recruitment Status* was "Completed". Note that no other criteria were pre-selected in the advanced feature. Likewise, under the *Show/Hide Column* option, variables explained in [Table 1](#tbl0001){ref-type="table"} were extracted. This query resulted in the database "Clinical Trials.dta" attached to this article.Table 1Databases and variables used.Table 1Stata Database (raw data)VariablesDescriptionClinical TrialsNCT NumberUnique identifier for each clinical trialPrimary Completion DateDate that the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measureCompletion DateLast participant\'s last visitTitleName of the clinical trialStatusidUnique identifier for each drugstatusWhether the drug was marketed, approved, dormant or canceleddateDate when each status was achievedDrugidUnique identifier for each drugtypeWhether the drug is human, veterinary or disinfectantIngredientsidUnique identifier for each drugactiveingCode for each active ingredient•For NMD and NAI, three tables were downloaded directly from <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database/what-data-extract-drug-product-database.html>. These contained information on drugs approved for use in Canada and can be found in the website under the names: QRYM_STATUS, QRYM_DRUG_PRODUCT, and QRYM_ACTIVE_INGREDIENTS. Attached to this article these are included as "Status.dta", "Drug.dta", and "Ingredients.dta", respectively. The three databases made available are reduced to the variables of interest included in [Table 1](#tbl0001){ref-type="table"}.

[Table 1](#tbl0001){ref-type="table"} outlines all variables included in the Stata data files attached to this paper after performing the previous queries. These are the ones needed to obtain the technology proxies. Readers can refer to the original sources for consulting and exploring availability of additional information.

From the information extracted, code is provided to process the raw data and obtain our three variables for medical technology. Steps taken to clean the data are outlined below:•The number of clinical trials was obtained by counting number of trials using the "NCT Number" and their primary completion date. This was used over the variable "completion date" given the high number of missing values in the latter one.•To construct the variables NMD and NAI all three files (databases) were merged using each drug unique identifier "id". First, from the "Status.dta" file we extracted drugs under the "marketed" status. (Once a drug is approved, it can become available for sale. After this step, it becomes a "marketed" product. All marketed products are also approved products). The first "date" the drug in question appears under the \"marketed\" category is chosen because the aim is to select the month a drug was initially marketed. Additional information is included in the database to help track the history of the product. For example, if a subsequent Notice of Compliance is issued for a drug (e.g. if the company filed a submission for a new indication, a change in manufacturer, etc.) it will appear as another "Marketed" and/or "Approved" status in the database at a later date. Second, from the "Drug.dta" file using the "type" variable only human drugs were kept. The number of NMD is then the count of all human drugs by the date they were first marketed. Lastly, from the "Ingredients.dta" file those drugs that are "highly innovative" were identified to obtain NAI. This was done by flagging the first time an active ingredient had been used in a drug (using each\'s drugs marketed date and "activeing" code). Notice that one drug can have several active ingredients; a "highly innovative" drug requires one or more of its active ingredients to be in use for the first time.

The original data for each of the three medical technology variables are in the form of a flow. They are converted to stock variables using the perpetual inventory method, as shown in the attached excel spreadsheet. The stock constructed series incorporate the obsolescence of medical technology under different depreciation rates. [Table 2](#tbl0002){ref-type="table"} shows descriptive statistics of the initial (flow form) and processed (stock form) data. Processed data include a 10% depreciation rate. Series with 5% and 15% depreciation rates are also included in the spreadsheet attached to this article to facilitate sensitivity analysis in applied research. The conversion to a stock variable results in a continuous time series even though some months have no new drug or clinical trial registrations.Table 2Descriptive statistics.Table 2Flow variablesStock variables (10% depreciation)*NAINMDCTNAINMDCT*Mean3.1134.16415.5927.77329.963919.90Standard Error0.121.4522.200.3111213.60Median326.5040427.34266.423019.66Standard Deviation1.8423.04352.434.84174.593390.83Sample Variance3.40531.01124,209.7723.4530,481.6711,497,729.31Kurtosis0.701.87−1.040.44−1.17−1.71Skewness0.931.330.340.480.560.15Range9131143131.54615.919003Minimum14011.6580.805.52Maximum10135143143.19696.719008.52Sum7198609104,7286996.7983,150.82987,813.95Count231252252252252252

[Figure 1](#fig0001){ref-type="fig"} shows a graphical representation of the monthly data (241 data points) for both flow and stock variables.Fig. 1Medical technology variables.Fig. 1
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